Cite
HARVARD Citation
Schwartzberg, L. et al. (n.d.). 3089 Symptom analysis and quality of life (QoL) in patients treated with nivolumab (NIVO) as ≥2nd line therapy for advanced non-small cell lung cancer (aNSCLC). European journal of cancer. pp. S628-S629. [Online].